Drug Trial Radar · NCT03880825
Drug Interaction Study of Levoketoconazole and Metformin
Last checked: Nov 20, 2026Latest source record: Aug 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 28, 2019
Primary completion
May 3, 2019
Study completion May 3, 2019
Sponsor
- Lead sponsor
- Cortendo ABIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase I, open-label, fixed-sequence drug-drug interaction study to evaluate the effect of levoketoconazole on the single-dose PK of metformin in health subjects.
Conditions
- Healthy Subjects
Interventions
Metformin 500 mg Oral TabletDrug
single dose
Levoketoconazole 150 - 600 mg (BID)Drug
escalating dose from 150 mg to 600 mg (BID)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of metforminTime frame: 48 hours
- Time to maximum concentration (Tmax) of metforminTime frame: 48 hours
- Area under the plasma concentration-time curve (AUC) of metforminTime frame: 48 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinical Pharmacology of Miami, LLC
Miami, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.